Paper Details

  1. Home
  2. Paper Details

Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.

Author: DricotLaurence, HanseeuwBernard, IvanoiuAdrian, LhommelRenaud, MaloteauxJean-Marie, OctaveaJean-Noël, PierrotNathalie, QuenonLisa, SindicChristian

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Targretin® (bexarotene) has been shown to improve memory performance and biological markers in a single patient with mild Alzheimer's disease (AD). After 6 months of treatment with 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20%. No significant side effects were observed.
Paper Details　
Original Abstract of the Article :
We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3233/JAD-150405

データ提供：米国国立医学図書館（NLM）

Targretin: A Potential Oasis for Alzheimer's Disease

The world of [Alzheimer's disease (AD)] is a challenging one, often characterized by progressive cognitive decline. This case report explores the effects of Targretin® (bexarotene), a Retinoic X Receptor (RXR) agonist, on cognition and biomarkers in a patient with mild AD. The researchers observed significant improvement in memory and a reduction in tau protein levels in the cerebrospinal fluid after 6 months of treatment, suggesting the potential of Targretin® as a therapeutic agent for AD.

A Glimmer of Hope in the Desert of Alzheimer's

The researchers observed a remarkable improvement in memory and a reduction in tau protein levels in the cerebrospinal fluid after 6 months of treatment with Targretin® in a single patient with mild AD. While further research is needed to confirm these findings in larger studies, this case report offers a glimmer of hope for those seeking to slow down the progression of this devastating disease.

A New Path in the Fight Against AD

This case report highlights the potential of Targretin® as a therapeutic agent for AD. While further research is needed to confirm its efficacy and safety, the findings suggest that targeting RXR could be a promising approach for treating AD.

Dr.Camel's Conclusion

This case report offers a promising glimpse into the potential of Targretin® as a therapeutic agent for Alzheimer's disease. It's like finding a hidden oasis in the vast and unforgiving desert of AD, offering hope for a new path towards treatment and a brighter future for those affected by this devastating disease.

Date :
  1. Date Completed 2016-09-12
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26444777

DOI: Digital Object Identifier

10.3233/JAD-150405

Related Literature

Article Analysis
・Side Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.